A Clinical Study on Oncolytic Virus Injection (R130) for the Treatment of Advanced Bone and Soft Tissue Tumors
Status:
Recruiting
Trial end date:
2026-07-12
Target enrollment:
Participant gender:
Summary
9 participants are expected to be enrolled for this open，Single-armed clinical trial to
evaluate the safety and efficacy of the recombinant herpes simplex virus Ⅰ, R130 in patients
with advanced bone and soft tissue tumors.
Phase:
Early Phase 1
Details
Lead Sponsor:
Shanghai Yunying Medical Technology
Collaborator:
Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine